Selecta wins allergy deal with Sanofi worth up to $900 mln
PARIS Nov 28 (Reuters) - U.S. vaccine company Selecta Biosciences has signed a deal worth as much as $900 million with French drugmaker Sanofi to develop therapies for life-threatening food allergies, it said on Wednesday.
Under the deal, Sanofi will have an exclusive licence to develop a first food allergy therapy, with an option to develop two more, Selecta said in a statement.
Sanofi will have access to Selecta's Synthetic Vaccine Particle platform, which engineers tiny particles that produce tolerance to specific substances that provoke allergies.
"In allergies, as well as auto-immune diseases, organ transplantation and protein-replacement therapies, there is a lack of specific, effective and safe treatments to prevent undesired immune reactions," Selecta Chief Executive Werner Cautreels said in a statement.
"Our approach addresses the underlying causes of these diseases and thereby makes advances beyond today's symptomatic treatments and allergen-avoidance strategies."
Selecta said it was entitled to receive payments totalling $300 million for each allergy therapy under the deal with Sanofi, as well as royalties on sales.
Selecta's pipeline includes vaccines for stopping smoking and malaria, and immunotherapies for Type-1 diabetes and allergies.
- Maine nurse fights Ebola quarantine, says will not be bullied |
- SoftBank's humanoid robot lands job as Nescafe salesman
- Dollar surges as Fed ends QE on hawkish note
- Clashes erupt as Israeli police kill Palestinian suspected of shooting Jewish far-rightist
- Ukraine gas supplies in doubt as Russia seeks EU payment deal